Incyte Stock - Stifel lifts price target after bile duct disease data
19.06.2026 - 21:57:15 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 21:55 UTC. Details in the imprint.
Incyte (US45337C1027) drew analyst attention this week after partner Mirum Pharmaceuticals reported positive phase 2 data for bile duct disease candidate zilurgisertib in primary sclerosing cholangitis. Stifel responded by raising its price target on Incyte shares and reiterating a Buy rating, according to a broker summary of the move.
All news and analysis on Incyte stock
Stay on top of recent trial readouts, analyst actions and market data for Incyte with our dedicated topic page and the company’s own investor information.
What Stifel changed on Incyte
According to a recent broker note summary, Stifel increased its price target on Incyte shares from $120 to $123 and kept a Buy recommendation in place, citing the positive phase 2 results with partner Mirum’s zilurgisertib in primary sclerosing cholangitis.
The analyst firm highlighted the bile duct disease program as an incremental value driver within Incyte’s broader inflammation and autoimmunity pipeline. The adjustment represents a modest upward revision but signals continued confidence in the company’s late-stage assets.
How Incyte compares in the biotech peer group
Incyte sits in a competitive US mid-to-large-cap biotech cohort that includes companies such as Vertex Pharmaceuticals and Gilead Sciences, where differentiated specialty products and late-stage pipelines are key valuation drivers across the Standard & Poor's 500 index and the broader Nasdaq biotechnology segment.
Against this backdrop, analyst actions like Stifel’s target lift on Incyte can influence how investors weigh the stock relative to peers with similar focus areas in oncology and immunology, even when the absolute change in target is relatively small.
How the company makes money
Incyte generates most of its revenue from hematology and oncology medicines, led by Jakafi (ruxolitinib), a JAK1/JAK2 inhibitor for myelofibrosis, polycythemia vera and graft-versus-host disease that it markets in the United States under a collaboration with Novartis for ex-US rights.
Where the stock trades today
Incyte shares (US45337C1027) trade on Nasdaq under the ticker INCY; the most recently available price and market data are quoted in US dollars on the US exchange.
Key facts on Incyte stock
- Company: Incyte Corp.
- ISIN: US45337C1027
- WKN: 896133
- Ticker: INCY
- Venue: Nasdaq
- Sector / Industry: Health Care / Biotechnology
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
